DUBLIN–(BUSINESS WIRE)–The “Global Uveitis treatment Market 2020-2026” report has been added to ResearchAndMarkets.com’s offering. The global uveitis treatment market is projected to witness considerable growth during the forecast period. The major f…
Author: Business Wire
Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Thursday, February 25, 2021
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glauco…
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with …
Global Eyewear Market (2021 to 2026) – Industry Trends, Share, Size, Growth, Opportunity and Forecasts – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Eyewear Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026” report has been added to ResearchAndMarkets.com’s offering. The global eyewear market reached a value of US$ 127.8 Billion in…
National Vision Holdings, Inc. Announces Fourth Quarter 2020 Earnings Release and Conference Call
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) will report its fourth quarter 2020 financial results before the market opens on Wednesday, March 3, 2021. The Company will host a conferenc…
jCyte Announces Expansion of its Executive Leadership Team with Appointments in Commercial, Clinical and Manufacturing Operations
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–jCyte Announces Expansion of its Executive Leadership Team with Appointments in Commercial, Clinical and Manufacturing Operations
Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts
WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that Express Scripts,…
Global Dry Eye Medication Market Report 2020-2030 – Major Players are Novartis, Allergan, Otsuka, Santen Pharmaceutical and Auven Therapeutics – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Dry Eye Medication Global Market Report 2020-30: COVID-19 Impact and Recovery” report has been added to ResearchAndMarkets.com’s offering. The global dry eye medication market is expected to decline from $3.8 billion in 20…
Global Eye Health Supplements Market (2020 to 2026) – by Formulation, Indication, Ingredient Type and Region – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Eye Health Supplements Market By Formulation, By Indication, By Ingredient Type, By Region, Industry Analysis and Forecast, 2020 – 2026” report has been added to ResearchAndMarkets.com’s offering. The Global Eye Hea…
GenSight Biologics Announces Publication of Results from LUMEVOQ® Phase I/IIa Clinical Trial REVEAL in BioDrugs
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative dis…
Gyroscope Therapeutics Announces Positive Interim Data from Phase I/II FOCUS Trial of Investigational Gene Therapy GT005
LONDON–(BUSINESS WIRE)–Gyroscope Therapeutics Announces Positive Interim Data from Phase I/II FOCUS Trial of Investigational Gene Therapy GT005.
Gyroscope Therapeutics Announces Positive Interim Data from Phase I/II FOCUS Trial of Investigational Gene Therapy GT005
LONDON–(BUSINESS WIRE)–Gyroscope Therapeutics Announces Positive Interim Data from Phase I/II FOCUS Trial of Investigational Gene Therapy GT005.
Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2021 – Virtual Edition
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, annou…
New Phase III Data Show Genentech’s Faricimab Is the First Investigational Injectable Eye Medicine to Extend Time Between Treatments up to Four Months in Two Leading Causes of Vision Loss, Potentially Reducing Treatment Burden for Patients
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from four Phase III studies of its investigational bispecific antibody, faricimab, for the treatment of d…
NextGen® Patient Experience Platform Adopted by Lone Star Circle of Care Network
ATLANTA–(BUSINESS WIRE)—- $NXGN #AmbulatoryHealthcare–Community Health Centers in Texas Improve Patient Engagement with Well-Integrated Capabilities leveraging NextGen® Patient Experience Platform.
Blinded Veterans Association Endorses Bosma Enterprises’ Good Works® Ice Melter
INDIANAPOLIS–(BUSINESS WIRE)–The Blinded Veterans Association (BVA) today announced its endorsement of Bosma Enterprises’ Good Works® Ice Melter. BVA is the nation’s only congressionally chartered Veterans Service Organization (VSO) created for visua…
STAAR Surgical to Report Fourth Quarter and Fiscal Year Results on February 24, 2021
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the…
Global RG 7774 Pipeline Report 2021: Phase II (NCT04265261) of Clinical Trial for Diabetic Retinopathy – Emerging Insight and Market Forecast to 2030 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “RG 7774 – Emerging Insight and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering. This report provides comprehensive insights about an investigational product for Diabetic Retinopathy in 7 …
What Do Doctors Want in 2021? Sixth Annual Predictions Report from Apollo Intelligence Shows Rising Need for Increased Drug Discovery, Along with Lower Drug Costs
WATERTOWN, Mass.–(BUSINESS WIRE)–What do doctors want in 2021? New data from Apollo Intelligence show more interest in drug discovery, lower drug prices, concern for data privacy.
Trefoil Therapeutics Begins Second Phase 2 “STORM” Clinical Trial with Regenerative Treatment for Fuchs Endothelial Corneal Dystrophy
SAN DIEGO–(BUSINESS WIRE)–Trefoil Therapeutics begins second Phase 2 “STORM” clinical trial with regenerative treatment for Fuchs Endothelial Corneal Dystrophy